Evofem Biosciences, Inc.

OTCPK:EVFM Voorraadrapport

Marktkapitalisatie: US$1.4m

Evofem Biosciences Beheer

Beheer criteriumcontroles 2/4

Evofem Biosciences' CEO is Saundra Pelletier, appointed in Jan 2018, has a tenure of 6.83 years. total yearly compensation is $1.52M, comprised of 36.9% salary and 63.1% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth $22.35. The average tenure of the management team and the board of directors is 1.6 years and 6.8 years respectively.

Belangrijke informatie

Saundra Pelletier

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris36.9%
Dienstverband CEO6.8yrs
Eigendom CEO0.002%
Management gemiddelde ambtstermijn1.6yrs
Gemiddelde ambtstermijn bestuur6.8yrs

Recente managementupdates

Recent updates

Evofem partners with a360 Media to support Phexxi prescription growth

Jul 21

Evofem announces peer-reviewed publication on birth control method

Jul 12

Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier

Jul 06

Evofem announces U.S. patent win for birth control method

Jun 30

Evofem: ACA Coverage Of Phexxi Is A Game Changer

Jan 18

Analyse CEO-vergoeding

Hoe is Saundra Pelletier's beloning veranderd ten opzichte van Evofem Biosciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

US$57m

Mar 31 2024n/an/a

US$47m

Dec 31 2023US$2mUS$560k

US$50m

Sep 30 2023n/an/a

US$44m

Jun 30 2023n/an/a

US$67m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$1mUS$812k

-US$78m

Sep 30 2022n/an/a

-US$119m

Jun 30 2022n/an/a

-US$283m

Mar 31 2022n/an/a

-US$192m

Dec 31 2021US$3mUS$812k

-US$206m

Sep 30 2021n/an/a

-US$194m

Jun 30 2021n/an/a

-US$150m

Mar 31 2021n/an/a

-US$169m

Dec 31 2020US$4mUS$781k

-US$142m

Sep 30 2020n/an/a

-US$114m

Jun 30 2020n/an/a

-US$98m

Mar 31 2020n/an/a

-US$81m

Dec 31 2019US$3mUS$847k

-US$80m

Sep 30 2019n/an/a

-US$82m

Jun 30 2019n/an/a

-US$87m

Mar 31 2019n/an/a

-US$75m

Dec 31 2018US$8mUS$738k

-US$126m

Sep 30 2018n/an/a

-US$131m

Jun 30 2018n/an/a

-US$188m

Mar 31 2018n/an/a

-US$172m

Dec 31 2017US$2mUS$731k

-US$109m

Compensatie versus markt: Saundra's total compensation ($USD1.52M) is above average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: Saundra's compensation has been consistent with company performance over the past year.

CEO

Saundra Pelletier (54 yo)

6.8yrs

Tenure

US$1,520,455

Compensatie

Ms. Saundra Pelletier has been Chief Executive Officer and President of Evofem Biosciences, Inc. since January 17, 2018. She is an Independent Director at Windtree Therapeutics, Inc. since August 13, 2024....

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Saundra Pelletier
Interim Chair6.8yrsUS$1.52m0.0016%
$ 22.4
Ivy Zhang
CFO & Secretary1.6yrsUS$438.85k0.00010%
$ 1.4
Amy Raskopf
Chief Business Development Officer & Senior VP of Investor Relationsno datageen gegevensgeen gegevens
Ellen Thomas
Chief of Staffno datageen gegevensgeen gegevens
Kathy Gallo-Doyle
Senior Vice President of Commercial Operationsless than a yeargeen gegevensgeen gegevens

1.6yrs

Gemiddelde duur

Ervaren management: EVFM's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Saundra Pelletier
Interim Chair6.8yrsUS$1.52m0.0016%
$ 22.4
Colin Rutherford
Independent Director6.8yrsUS$70.00k0%
$ 0
Lisa Rarick
Independent Director4.8yrsUS$55.00k0%
$ 0
Kim Kamdar
Independent Director6.8yrsUS$77.62k0.000010%
$ 0.1
Tony O'Brien
Independent Director6.8yrsUS$75.00k0%
$ 0

6.8yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: EVFM's board of directors are considered experienced (6.8 years average tenure).